Legal & General Group Portfolio holdings
Legal & General Group Plc, founded in 1836 by six lawyers in London, is a British multinational financial services company headquartered in London, renowned for its leadership in insurance, pensions, and investment management. Managing trillions in assets, the firm operates through key divisions like Legal & General Investment Management (LGIM), one of the UK’s largest asset managers, focusing on index funds, active strategies, and sustainable investing for institutional clients like pension funds. It also provides life insurance, retirement products, and general insurance, serving millions of customers with a strong emphasis on long-term financial security and infrastructure investment, such as affordable housing. With a heritage of stability and a modern push toward ESG (environmental, social, governance) principles, Legal & General remains a cornerstone of the UK financial landscape with a growing global presence.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$657M |
| 2 |
Apple
AAPL
|
+$610M |
| 3 |
Amazon
AMZN
|
+$587M |
| 4 |
AstraZeneca
AZN
|
+$319M |
| 5 |
Snowflake
SNOW
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$323M |
| 2 |
MXIM
Maxim Integrated Products
MXIM
|
+$273M |
| 3 |
WORK
Slack Technologies, Inc.
WORK
|
+$121M |
| 4 |
PFPT
Proofpoint, Inc.
PFPT
|
+$98.6M |
| 5 |
JD.com
JD
|
+$89.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.03% |
| 2 | Financials | 13.72% |
| 3 | Healthcare | 12.6% |
| 4 | Consumer Discretionary | 10.97% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2726
Karyopharm Therapeutics
KPTI
$48M
| $175K | ﹤0.01% |
2,003
+781
| +64% | +$81.1K |
|
2727
Expro Ltd
XPRO
$1.91B
| $175K | ﹤0.01% |
9,913
+5,152
| +108% | +$87.4K |
|
|
ALBO
2728
DELISTED
Albireo Pharma Inc
ALBO
| $175K | ﹤0.01% |
5,588
+3,022
| +118% | +$93.5K |
|
2729
Regis Corp
RGS
$70.2M
| $174K | ﹤0.01% |
2,507
+58
| +2% | +$7.62K |
|
2730
Rhythm Pharmaceuticals
RYTM
$7.96B
| $173K | ﹤0.01% |
13,263
+6,811
| +106% | +$104K |
|
2731
MiMedx Group
MDXG
$633M
| $171K | ﹤0.01% |
28,228
+14,293
| +103% | +$161K |
|
|
SRG
2732
Seritage Growth Properties
SRG
$136M
| $170K | ﹤0.01% |
11,459
+7,349
| +179% | +$116K |
|
2733
Amerant Bancorp
AMTB
$1.13B
| $169K | ﹤0.01% |
6,820
+4,298
| +170% | +$101K |
|
2734
Banco Santander Chile
BSAC
$16.6B
| $169K | ﹤0.01% |
8,558
| – | – |
|
|
KRON
2735
DELISTED
Kronos Bio
KRON
| $167K | ﹤0.01% |
8,001
+3,323
| +71% | +$71.4K |
|
2736
Phathom Pharmaceuticals
PHAT
$692M
| $167K | ﹤0.01% |
5,178
+2,739
| +112% | +$91K |
|
2737
Telecom Argentina
TEO
$5.96B
| $166K | ﹤0.01% |
33,508
+992
| +3% | +$5.11K |
|
|
KBAL
2738
DELISTED
Kimball International
KBAL
| $166K | ﹤0.01% |
14,794
+7,251
| +96% | +$89.1K |
|
|
CMRX
2739
DELISTED
Chimerix, Inc.
CMRX
| $165K | ﹤0.01% |
26,608
+14,393
| +118% | +$99K |
|
|
ICPT
2740
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $165K | ﹤0.01% |
11,132
-4,156
| -27% | -$66.5K |
|
2741
Hovnanian Enterprises
HOV
$807M
| $164K | ﹤0.01% |
1,703
+984
| +137% | +$98.2K |
|
2742
Ecovyst
ECVT
$1.14B
| $163K | ﹤0.01% |
13,998
+6,964
| +99% | +$95.1K |
|
2743
Inseego
INSG
$90.5M
| $163K | ﹤0.01% |
2,444
+1,466
| +150% | +$123K |
|
2744
Energy Fuels
UUUU
$3.53B
| $162K | ﹤0.01% |
23,059
+379
| +2% | +$2.16K |
|
|
TGH
2745
DELISTED
Textainer Group Holdings limited
TGH
| $161K | ﹤0.01% |
4,641
| – | – |
|
2746
Hackett Group
HCKT
$287M
| $160K | ﹤0.01% |
8,152
+4,971
| +156% | +$93.1K |
|
2747
EverQuote
EVER
$906M
| $158K | ﹤0.01% |
8,492
+3,016
| +55% | +$72.2K |
|
2748
Midland States Bancorp
MSBI
$695M
| $158K | ﹤0.01% |
6,386
+3,811
| +148% | +$94.9K |
|
2749
Korro Bio
KRRO
$195M
| $157K | ﹤0.01% |
445
+94
| +27% | +$37K |
|
2750
Bank First Corp
BFC
$1.7B
| $156K | ﹤0.01% |
2,208
+1,371
| +164% | +$95.5K |
|
Similar funds
Legal & General Group's Q3 2021 Portfolio in Review
As of Q3 2021, Legal & General Group held 3,551 positions worth $308B, up 2.9% from $299B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Legal & General Group deployed $10.7B of net new capital in Q3 2021, opening 77 new positions and adding to 2,293 existing holdings. Its largest new stake was AstraZeneca: 2,738,007 shares worth $329M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was JD.com, an estimated $89.3M trimmed.
- Legal & General Group's largest Q3 2021 buy was AstraZeneca: 2,738,007 shares worth $329M.
- Legal & General Group added most to Microsoft in Q3 2021, an estimated $657M increase.
- Legal & General Group's biggest Q3 2021 reduction was JD.com, cutting an estimated $89.3M.
- Legal & General Group fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $323M.
- Legal & General Group's ten largest holdings make up 22% of its $308B portfolio in Q3 2021.
- Legal & General Group opened 77 new positions and closed 55 in Q3 2021.
- Legal & General Group's portfolio value rose 2.9% quarter-over-quarter to $308B.
Based on Legal & General Group's 13F filing for Q3 2021, filed 15 Nov 2021.